GCircular Dichroism Spectrometers Market Size

Statistics for the 2023 & 2024 GCircular Dichroism Spectrometers market size, created by Mordor Intelligence™ Industry Reports. GCircular Dichroism Spectrometers size report includes a market forecast to 029) and historical overview. Get a sample of this industry size analysis as a free report PDF download.

Market Size of GCircular Dichroism Spectrometers Industry

Circular Dichroism Spectrometers Market Size
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR (2024 - 2029) 6.50 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

GCircular Dichroism Spectrometers Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Circular Dichroism Spectrometers Market Analysis

The GCircular Dichroism Spectrometers Market is expected to register a CAGR of 6.5% during the forecast period(2024-2029).

  • The COVID-19 pandemic significantly impacted the market initially due to the lockdown restrictions imposed by the countries to control the spread of the virus, thereby impacting research and development activities. But during the late pandemic, very intensive research and development activities were started to find a cure for SARS-CoV-2 virus infection in which circular dichroism spectrometers were also used for the understanding of the molecular structure and chiral activities of biomolecules such as protein and DNA. 
  • For instance, according to the research study published in June 2021 in NCBI, circular dichroism is a common technique in biochemistry, structural biology, and pharmaceutical chemistry, and it is a widely used method for examining the structures and conformational changes of proteins. Therefore, the outbreak of the pandemic increased research activities, which in turn propelled the demand for circular dichroism spectrometers. Thus, the market witnessed considerable growth during the pandemic. Furthermore, the market has seen a surge post-pandemic due to the increased adoption of circular dichroism spectrophotometers in the development of vaccines for COVID-19.
  • The increasing popularity of biologics and increasing investments by private and public sectors in the R&D of biopharmaceuticals are the major factors propelling the market growth. The circular dichroism spectrometers are used in the study of molecular structure and chiral activities of biomolecules, and their use is expected to increase with the growing popularity and usage of biopharmaceuticals or biologics (for example, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) among others) that are used in the treatment of various chronic and rare diseases.
  • For instance, according to the April 2022 report of the American Cancer Society, biologics are used in the treatment of cancer in many ways and are being used widely for the treatment. Furthermore, in June 2022, Amgen Inc. received approval for RIABNI (rituximab-Marx), a biosimilar to Rituxan, from the United States Food and Drug Administration for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies in combination with methotrexate. Hence, the growing usage of biologics drugs and their potential in treating various diseases is expected to increase intensive research and development activities, where circular dichroism spectrometers are used in the analysis of biomolecules, and thus, the demand for circular dichroism spectrometers is expected to increase over the forecast period that is expected to boost growth in the studied market.
  • Moreover, the growing research and development activities, along with new investments in the area by the government as well as private entities, are expected to fuel growth in the circular dichroism spectrometers market over the forecast period. For instance, in August 2022, Innovent Biologics of China and Paris-based Sanofi would invest USD 2.42 billion in the biopharma group to jointly develop two cancer drugs in China. As per Innovent Biologics, SAR408701, or tusamitamab ravtansine, would be used to treat lung, gastric, and other cancers, while SAR444245, or non-alpha IL-2, was under phase-II studies for skin cancer, head, and neck tumors, among others.
  • In addition, in June 2022, the Rare Disease division of AstraZeneca, Alexion, spent about EUR 65 million (USD 68.6 million) to expand its manufacturing capabilities in Ireland, and over the next 18 months, the investment will be used by the company to build up its biologics manufacturing capacity and increase research and development initiatives in the country. Therefore, due to the above-mentioned factors, the demand for circular dichroism spectrometers is expected to increase; thereby considerable market growth is anticipated over the forecast period.
  • Therefore, the rising investments in the development of biologics and biopharmaceuticals, along with the increasing investments by private and public sectors in R&D, are the factors expected to drive the market growth. However, the lack of skilled professionals is expected to restrain the growth of the circular dichroism spectrometers market over the forecast period.

Circular Dichroism Spectrometers Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)